# Melanotan and the Approved Drug It Is Not

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-21 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/melanotan-versus-the-approved-one

> An approved melanocortin-1 receptor agonist exists: afamelanotide, for preventing phototoxic pain in erythropoietic protoporphyria, given as a 16 mg implant under supervision. Melanotan II, sold for cosmetic tanning, is not that drug.

## Key points

- Afamelanotide is approved in the EU and, since October 2019, in the US to prevent phototoxicity in erythropoietic protoporphyria, as a 16 mg implant.
- Its phase 3 trial measured pain-free time in sunlight, not tanning or appearance.
- Melanotan II sold online is unapproved, self-injected at a buyer-chosen dose, with no identity or purity guarantee.
- We could not retrieve the text of the most-cited melanoma case report, so no claim here rests on it.

There is an approved melanocortin-1 receptor agonist. It is called afamelanotide, it went through phase 3 trials, and it is approved in the EU and, since October 2019, in the US[2] for one thing: preventing phototoxicity in adults with erythropoietic protoporphyria, a rare disorder in which sunlight causes pain. It is given as a biodegradable controlled-release implant containing 16 mg, under medical supervision.[1] Melanotan II sold online for cosmetic tanning is not that drug, and the difference is the whole point.

## What the approved one is for

Erythropoietic protoporphyria is a genetic condition in which exposure to light causes burning pain. In the phase 3 trial CUV039, afamelanotide improved light tolerance: patients spent more time in direct sunlight without pain, and it took longer for the first symptoms of phototoxicity to appear under a standardized light source. It was generally well tolerated, with no drug-related serious adverse events reported; common reactions were headache and implant-site reactions.[1]

Look closely at that indication. The drug is approved to let people with a painful genetic photosensitivity disorder go outside. It is not approved to make anyone browner, and the trials measured pain-free time in sunlight, not appearance.

## The four differences that matter

*Why the existence of an approved analog says little about an unapproved one.*

|   | Afamelanotide | Melanotan sold online |
| --- | --- | --- |
| Regulatory status | Approved (EU and US) for a named condition[1][2] | Unapproved research chemical |
| Purpose | Preventing phototoxic pain in EPP | Cosmetic tanning |
| Form and dose | 16 mg controlled-release implant | Self-injected, dose set by the buyer |
| Oversight | Prescribed and administered clinically | None |

> A controlled-release implant placed by a clinician delivers a known quantity over a known period. A vial of powder reconstituted at home and injected to effect does not. Even if the molecules were identical (afamelanotide and Melanotan II are not), those are different exposures, and dose is most of what determines whether a drug is a medicine or a problem.

## What we are not claiming, and why

Melanotan is frequently discussed in connection with changing moles and with melanoma. There is published case-report literature on that association. The most-cited example has no abstract we could read, only a title and errata. **We did not verify those case details, so we are not building a claim on them.**

What can be said without that literature is enough to act on. A compound that stimulates melanocytes, taken at an unmeasured dose, without supervision, for a cosmetic purpose, by people who are by definition seeking more pigment change than their skin produces on its own, is not a situation in which anyone is monitoring their moles. That is a reason for caution regardless of what any individual case report says.

- Melanotan is not approved anywhere for cosmetic tanning.
- Products sold under the name are research chemicals with no identity, purity or dose guarantee.
- The existence of an approved melanocortin agonist for a rare photosensitivity disorder is not evidence for an unapproved analog used cosmetically.
- Any new, changing or asymmetric mole is worth showing to a doctor, and more so if you are using something that acts on melanocytes.

[Bremelanotide (PT-141)](https://glpwatchdog.org/peptides/pt-141), a melanotan II analog, did become an approved drug, for one narrow use; see [what the PT-141 evidence shows](https://glpwatchdog.org/research/pt-141-bremelanotide-evidence). For the regulatory position on research-use peptides generally, see [what FDA actually said about BPC-157](https://glpwatchdog.org/research/bpc-157-what-fda-actually-said). Full profiles of individual peptides are at [/peptides](https://glpwatchdog.org/peptides).

## Frequently asked questions

### Is melanotan approved?

Not for cosmetic tanning, anywhere. A related melanocortin-1 receptor agonist, afamelanotide, is approved in the EU and the US for preventing phototoxicity in adults with erythropoietic protoporphyria (a rare genetic photosensitivity disorder), as a 16 mg controlled-release implant.

### Isn't afamelanotide the same thing?

No. Afamelanotide is the peptide also known as Melanotan I, but Melanotan II, the tanning peptide this page is about, is a different compound. Afamelanotide is approved for a different purpose, delivered as a clinician-placed implant at a controlled dose, under supervision. Melanotan sold online is self-injected at a dose the buyer chooses. Those are different exposures even setting the molecules aside.

### Does melanotan cause melanoma?

There is published case-report literature discussing that association. We could not retrieve the text of the most-cited example, so we are not making a claim about what those cases showed. Separately, anything that acts on melanocytes is a reason to have moles checked rather than assume.

### What did the approved drug's trial measure?

Time spent in direct sunlight without pain, and time to the first symptoms of phototoxicity under a standardized light source, in patients with erythropoietic protoporphyria. It did not measure tanning or appearance.

## References

1. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology. 2016. PMID: 26979527. https://pubmed.ncbi.nlm.nih.gov/26979527/
2. U.S. Food and Drug Administration Drugs@FDA: SCENESSE (afamelanotide) implant, NDA 210797, original approval October 8, 2019. FDA Drugs@FDA database. 2019. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797

---

Cite as: GLP Watchdog, Ruth Calder, "Melanotan and the Approved Drug It Is Not", published 2026-08-21, updated 2026-10-27. https://glpwatchdog.org/research/melanotan-versus-the-approved-one

Canonical HTML page: https://glpwatchdog.org/research/melanotan-versus-the-approved-one

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.